COMP <GO>
HROW vs AVLN // ALTMAN Z-SCORE & DEBT/EQUITY
Harrow Inc. (NASDAQ) VS. Avalyn Pharma Inc. (NASDAQ) • 15-METRIC TALLY: HROW 0
— AVLN 2
■ METRIC PARITY
LAST: $29.99 (+2.04%) • MKT CAP: $1.12B
balance-sheet
2.67
LAST: $25.71 (-0.12%) • MKT CAP: $1.14B
balance-sheet
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HROW VS. AVLN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HROW | AVLN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.10% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 42.90% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 33.6x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.82% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 11.20% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -1.90% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 36.40% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.67 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.5 | 44.2 | -5.66 | AVLN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.12B | $1.14B | -$15.5M | AVLN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HROW REV | AVLN REV | HROW GROSS % | AVLN GROSS % | HROW FCF | AVLN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $272.3M | $0 | 75.1% | — | $43.0M | — |
| FY 2024 | $199.6M | — | 75.3% | — | -$23.8M | — |
| FY 2023 | $130.2M | — | — | — | $3.8M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HROW // BETA —
AVLN // BETA —